TXG SCHEDULE 13G/A: SEC filing

T. Rowe Price Associates

Filed with the SEC on · accession 0000080255-26-000713

TXG filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. A report the company filed with the SEC (the US market regulator).

Summary of the filing

T. Rowe Price Associates filed an amended Schedule 13G indicating it beneficially owns 17,472,941 shares (14.5%) of 10x Genomics Class A common stock as of September 30, 2026, down from 16,779,529 shares previously reported.

Key details

shares beneficially owned$17.5M
percent of class beneficially owned$15
Beneficial owner / filerT. Rowe Price Associates, Inc.
Issuer10x Genomics, Inc.
Vice presidentEllen York

✦ Ask GOAX AI about this filing — what it means for TXG, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for TXG?

Click here

Frequently asked questions

What did TXG file with the SEC on Nov 16, 2026?

TXG filed a SCHEDULE 13G/A (SEC filing). T. Rowe Price Associates filed an amended Schedule 13G indicating it beneficially owns 17,472,941 shares (14.5%) of 10x Genomics Class A common stock as of September 30, 2026, down from 16,779,529 shares previously reported.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

Other TXG SEC filings

Get alerts when TXG files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days